Английская Википедия:Dacomitinib

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Infobox drug

Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[1]

Dacomitinib has advanced to several Phase III clinical trials.Шаблон:When The January 2014 results of the first trials were disappointing, with a failure to meet the study goals.[2][3][4] Additional Phase III trials are ongoingШаблон:When.[2]

In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.[5]

Dacomitinib was approved for medical use in the United States in September 2018,[6] in Japan in 2019, and in the European Union in 2019,[7] for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.

References

Шаблон:Reflist

External links

Шаблон:Targeted cancer therapeutic agents Шаблон:Growth factor receptor modulators Шаблон:Portal bar


Шаблон:Antineoplastic-drug-stub